1737 — Taiyen Biotech Co Income Statement

0.000.00%

Last trade - 00:00

Consumer DefensivesConservativeSmall CapContrarian

Annual income statement for Taiyen Biotech Co, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	3,130	4,096	3,614	3,409	3,238
Cost of Revenue
Gross Profit	1,308	1,373	1,277	1,257	1,321
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Total Operating Expenses	2,667	3,570	3,174	3,100	2,890
Operating Profit	463	526	440	309	348
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	464	510	531	329	433
Provision for Income Taxes
Net Income After Taxes	375	412	428	217	317
Minority Interest
Net Income Before Extraordinary Items
Net Income	365	393	427	300	372
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	365	393	427	300	372
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	1.83	1.98	2.15	1.52	1.88
Dividends per Share